RankingsPrimerArbiterPhysicistMathematicianContrarianQESites logClaimsSourcesResearch notes

PubMed / PMC / Europe PMC, 2026-10-04 (Investigator run 1)

Queries: - Google (Chrome): "PAP-IMI" OR Papimi study pubmed OR trial OR "case reports". - PMC article page opened in Chrome: https://pmc.ncbi.nlm.nih.gov/articles/PMC10001461/ - Europe PMC full text (curl): PMC10001461, PMC12385873, PMC12534222 -> research/files/europepmc-*.xml - PubMed E-utilities (curl): esearch PAPIMI OR PAP-IMI OR "PAP ion magnetic" (28 IDs; most are chemistry false hits on "PAP"); esummary -> research/files/pubmed-papimi-esummary.json; efetch PMID 11913824 -> research/files/pubmed-11913824-Leisner2002.txt

Relevant PubMed records: 11913824 (Leisner 2002), 36900946 (Viti 2023), 40868622 (Viti 2025), 40097846 (Keilani 2025). Possibly relevant, not checked: 25097875 (Efthimiadou 2014, "presowing pulsed electromagnetic treatment of tomato seed", Greek group; whether a PAPIMI device was used is unknown; note the "seed germinator" import declaration in the 2002 FDA EIR).

1. Leisner S, Shahar R, Aizenberg I, Lichovsky D, Levin-Harrus T (2002) [web] https://pubmed.ncbi.nlm.nih.gov/11913824/

"The effect of short-duration, high-intensity electromagnetic pulses on fresh ulnar fractures in rats." J Vet Med A Physiol Pathol Clin Med 49(1):33-7. Koret School of Veterinary Medicine, Hebrew University. - Device: "a new PEMF generator (PAP IMI)... unique by virtue of the extremely high power output of each of the pulses". Rats randomized to treatment or no treatment; 2-3 mm ulnar defect; weekly radiographs; histology at the end. - Result: "the healing process was faster in rats that were not treated by PEMF... the fibrous content of the callus in rats belonging to the treatment group was significantly higher". "The results of this study do not support the claim that PEMF generated by the PAP-IMI stimulate osteogenesis and bone healing". - Bears on claim 5. This is an independent, controlled animal test, and its result went against the claim. No sham device (untreated controls).

2. Viti A, et al. (2023) Int J Environ Res Public Health 20(5):3934, doi in record; PMC10001461 [web]

"Modulation of Heart Rate Variability following PAP Ion Magnetic Induction Intervention in Subjects with Chronic Musculoskeletal Pain: A Pilot Randomized Controlled Study." - Design: single-blind, randomized, placebo-controlled parallel pilot. n = 32 (PAP 17, SHAM 15). One session. The sham device was externally identical and deactivated. - Result: in the PAP group SDNN, RMSSD, NN50, pNN50 and HF increased significantly; the SHAM group showed no significant change. The authors call these "preliminary findings". - Device (as described by the authors, citing manufacturer refs 48-49): PAPIMI TM, Pulse Dynamics, Athens, model ASKLIPIOS; input 230 V, 2500 VA. "composed of a capacitor that stores electrical energy, which is then conducted through a plasma chamber (spark gap)... into a spiral coil applicator". "Due to very high voltages reaching up to 40kV and peak currents of several 10 kA, an energy output per pulse of about 60 W (joules) with a magnetic induction of 50-150 mT is achieved. Each pulse has a base frequency of about 240 kHz and a duration of about 50 us... pulse repetition rate can be varied between 1 and 8 Hz." - Earlier human PAPIMI reports cited (refs 40-42): refractory seizures, skin wound healing, fatigue syndrome (single-subject designs). Not retrieved. - Affiliations: Centro Fisioterapico Apuano (Lucca, a private physiotherapy centre) and Dept. of Experimental and Clinical Medicine, University of Florence. "The authors declare no conflict of interest." "This research received no external funding."

3. Viti A, et al. (2025) Healthcare (Basel); PMC12385873 [web]

"PAPIMI Short Effect on Pain Perception and Heart Rate Variability in Chronic Musculoskeletal Pain: A Pilot Study." - Single-arm, n = 30, one 30-min session at about 2.5 Hz, coil 18 cm diameter at about 4 cm from the skin. Pain score (NPRS) fell (p < 0.001; median -2, which meets the stated minimal clinically important difference); RMSSD (p = 0.015) and HF (p = 0.029) rose. No correlation between pain change and HRV change. No control group. - Same device description (40 kV, several 10 kA, about 60 J, 50-150 mT, 240 kHz, 50 us). - The company site papimi.com promotes this as "New Pilot Study" (and a separate page "Clinical Trial Confirms: papimi Reduces Back Pain by More Than 50% in Just 3 Sessions"; not opened). The company is an interested party.

4. Keilani M, et al. (2025) Wien Klin Wochenschr; PMC12534222 [web]

"Feasibility, acceptance and effects of pulsed magnetic field therapy in patients with post-COVID-19 fatigue syndrome: a randomized controlled pilot study." - Medical University of Vienna, Dept. of Physical Medicine, with Therme Wien Med / Ludwig Boltzmann Institute. Randomized, single-blinded, placebo-controlled pilot, n = 20 (10 + 10), 10 sessions of 30 min, twice weekly. Papimi Delta (Pulse Dynamics Ltd., Pipinou 1 & Souliou, 17342 Agios Dimitrios, Greece). - Result: improvement in the 6-minute walk test, fatigue (BFI, MFI), HADS depression, insomnia, work ability and SF-36 in the intervention group; three placebo drop-outs. - Device description: "The PEMF pulse is like a damped oscillation with a short pulse duration of ~50 us. The basic frequency is ~240 kHz. In the maxima and minima of the damped oscillation, high-frequency oscillation peaks in the megahertz to gigahertz range arise... High voltages (up to 40 kV) and peak currents (up to 10 kA) arise in the applicator spool... energy per pulse of about 96 Watt (Joule) with a magnetic flux density of 50-100 mT... penetration of the body tissue depth of about 20 cm" (citing manufacturer ref 10). - "M. Keilani... declare that they have no competing interests." Open access funded by the Medical University of Vienna.

How this bears on the claims

  • Claims 2-3: the burst-at-extrema waveform of patent FIG. 2-3 is still the device's design in 2023-2025. The trial papers add the electrical numbers the patent lacks (40 kV, about 10 kA, 60-96 J per pulse, base 240 kHz, about 50 us envelope). Contrast the patent's "low frequency" LCR curve and its "<1 us" bursts. These numbers are the manufacturer's, repeated by the authors; no paper reports its own field measurement.
  • Claim 5: since 2023 there are small sham-controlled or placebo-controlled trials (n = 32, n = 20) with positive physiological or symptomatic outcomes, and one controlled animal study (2002) with a negative bone-healing outcome. None measures transmembrane potential, resonant absorption by nitrogen, or cancer outcomes.
  • Claims 1 and 4 (gain, element-selective resonance): not addressed by any of these papers.